Oct 8, 2013

Posted by in Featured, Stock Market News | 0 Comments

Market Buzzers: Magnum Hunter Resources Corp(NYSE:MHR), Globalstar, Inc.(OTCMKTS:GSAT) Acorda Therapeutics (NASDAQ:ACOR) and JPMorgan Chase (NYSE:JPM)

Market Buzzers: Magnum Hunter Resources Corp(NYSE:MHR), Globalstar, Inc.(OTCMKTS:GSAT) Acorda Therapeutics (NASDAQ:ACOR) and JPMorgan Chase (NYSE:JPM)

JPMorgan Chase (NYSE:JPM) nominates Dana Deasy as the firm’s new Chief Information Officer; effective in December.

The company declared it has nominated Dana Deasy as the firm’s new Chief Information Officer, effective in December. In this job, Deasy will be serving for the company’s technology systems and infrastructure throughout all of its business globally.

Globalstar, Inc.(OTCMKTS:GSAT) settled +8.33% higher at $1.43 on high volume of 12.68 million shares during the last trading day. The stock has its 12-month high at $1.49 and 52-week low price was $0.25.

Globalstar, Inc. (Globalstar) is a provider of mobile voice and data communications services globally via satellite. Globalstar’s satellite communications business, by providing critical mobile communications to the Company’s subscribers, serves principally recreation and personal; government; public safety and disaster relief; oil and gas; maritime and fishing; natural resources, mining and forestry; construction; utilities and transportation.

Magnum Hunter Resources Corp(NYSE:MHR) saw its price fall on below-normal volume, as 12.00 million shares changed hands when compared with its average daily volume of 4.86 million shares. The stock was gained +6.99% to close at $7.04.

Magnum Hunter Resources Corporation (Magnum Hunter) is an independent oil and gas company engaged in the exploration for and the exploitation, acquisition, development and production of crude oil, natural gas and natural gas liquids, primarily in the states of West Virginia, Ohio, Texas, Kentucky and North Dakota and in Saskatchewan, Canada. T

Acorda Therapeutics (NASDAQ:ACOR) announced that the first patient has been enrolled in the second clinical trial of Glial Growth Factor 2 (GGF2). This Phase 1b single-infusion trial in people with heart failure will assess tolerability of three dose levels of GGF2, and also includes several explorative measures of efficacy.

Comments are closed.